Non-Small-Cell Lung Carcinoma Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280